INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V.
Van Den Bent M, et al. Among authors: whenham n.
Neuro Oncol. 2020 May 15;22(5):684-693. doi: 10.1093/neuonc/noz222.
Neuro Oncol. 2020.
PMID: 31747009
Free PMC article.
Clinical Trial.